Fundraising Fox诺令生物
Nanjing, CN · 1 known investors
Find your way into 诺令生物
Sign up to see every warm intro you have to 诺令生物
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 诺令生物 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Novlead (诺令生物) develops inhaled nitric oxide (iNO) therapy and diagnostic systems for cardiopulmonary disease, covering nitric oxide generation, delivery, detection, storage, and clinical use across ICU, inpatient, outpatient, and home-care settings. Founded in 2018, it serves hospitals and patients, with products deployed in over 800 hospitals across China and commercialized in 10 countries including France and Hungary.
Founders & leadership
毛
毛雯
Investors · 1
Frequently asked questions
- What does 诺令生物 do?
- Novlead (诺令生物) develops inhaled nitric oxide (iNO) therapy and diagnostic systems for cardiopulmonary disease, covering nitric oxide generation, delivery, detection, storage, and clinical use across ICU, inpatient, outpatient, and home-care settings. Founded in 2018, it serves hospitals and patients, with products deployed in over 800 hospitals across China and commercialized in 10 countries including France and Hungary.
- Who are 诺令生物's investors?
- 诺令生物's investors include TriWise Capital.
- Where is 诺令生物 headquartered?
- 诺令生物 is headquartered in Nanjing, CN.